Al-Dawaa Medical Services Company
4163.SRSAUHealthcare● Active
$43.82
+$0.26(+0.60%)
Market Cap$3.7B
P/E Ratio—
52W High$80.05
52W Low$43
Al-Dawaa Medical Services Company (4163.SR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
4163.SR · earnings · updated Jun 15, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
$0.72
Est. $0.89 · -19.1%
Revenue
$1.68B
Est. $1.79B · -6.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
4163.SR reports quarterly as a SAU-listed Medical - Pharmaceuticals company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
79
days
Expected Date
Sep 2, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away79
Expected DateSep 2, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 4, 2026 | $0.89 | $0.72 | -19.1% | $1.68B | $1.79B | -6.0% |
| — Q1 FY2026 | Mar 23, 2026 | $0.89 | $0.89 | +0.0% | $1.78B | $1.79B | -0.7% |
| ▼ Q4 FY2025 | Nov 4, 2025 | $1.00 | $0.81 | -18.7% | $1.70B | $1.70B | +0.1% |
| ▼ Q2 FY2025 | May 7, 2025 | $1.63 | $1.24 | -23.9% | $1.65B | $1.70B | -3.1% |
| ▲ Q1 FY2025 | Mar 17, 2025 | $0.89 | $1.22 | +37.1% | $1.75B | $1.60B | +9.3% |
| ▼ Q4 FY2024 | Nov 4, 2024 | $0.97 | $0.88 | -9.3% | $1.63B | $1.57B | +3.8% |
| ▼ Q3 FY2024 | Aug 4, 2024 | $1.27 | $1.13 | -11.0% | $1.59B | $1.52B | +4.1% |
| — Q2 FY2024 | Apr 30, 2024 | — | $1.12 | — | $1.52B | — | — |
Q2 FY2026
May 4, 2026Miss
EPS Actual
$0.72
EPS Est.
$0.89
EPS Surpr.
-19.1%
Revenue
$1.68B
Q1 FY2026
Mar 23, 2026
EPS Actual
$0.89
EPS Est.
$0.89
EPS Surpr.
+0.0%
Revenue
$1.78B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
$0.81
EPS Est.
$1.00
EPS Surpr.
-18.7%
Revenue
$1.70B
Q2 FY2025
May 7, 2025Miss
EPS Actual
$1.24
EPS Est.
$1.63
EPS Surpr.
-23.9%
Revenue
$1.65B
Q1 FY2025
Mar 17, 2025Beat
EPS Actual
$1.22
EPS Est.
$0.89
EPS Surpr.
+37.1%
Revenue
$1.75B
Q4 FY2024
Nov 4, 2024Miss
EPS Actual
$0.88
EPS Est.
$0.97
EPS Surpr.
-9.3%
Revenue
$1.63B
Q3 FY2024
Aug 4, 2024Miss
EPS Actual
$1.13
EPS Est.
$1.27
EPS Surpr.
-11.0%
Revenue
$1.59B
Q2 FY2024
Apr 30, 2024
EPS Actual
$1.12
EPS Est.
—
EPS Surpr.
—
Revenue
$1.52B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.89 | $0.89 | $0.89 | 1 |
| Q3 FY2025 | $1.00 | $1.00 | $1.00 | 1 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2025 | $1.63 | $1.63 | $1.63 | 1 |
| Q4 FY2024 | $0.89 | $0.89 | $0.89 | 1 |
| Q3 FY2024 | $0.97 | $0.97 | $0.97 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $1.7B | $1.8B | $1.9B | 2 |
| Q3 FY2025 | $1.7B | $1.7B | $1.7B | 2 |
| Q2 FY2025 | $1.7B | $1.7B | $1.8B | 3 |
| Q1 FY2025 | $1.7B | $1.7B | $1.7B | 1 |
| Q4 FY2024 | $1.6B | $1.6B | $1.6B | 3 |
| Q3 FY2024 | $1.5B | $1.6B | $1.6B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 4, 2026 | -19.1% | $46.80 | $46.80 | +0.00% |
| ▲ Q1 FY2026 | Mar 23, 2026 | +0.0% | $48.78 | $50.70 | +3.94% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -18.7% | $64.40 | $62.80 | -2.48% |
| ▼ Q2 FY2025 | May 7, 2025 | -23.9% | $83.40 | $86.00 | +3.12% |
| ▲ Q1 FY2025 | Mar 17, 2025 | +37.1% | $71.80 | $71.20 | -0.84% |
| ▼ Q4 FY2024 | Nov 4, 2024 | -9.3% | $88.40 | $86.50 | -2.15% |
| ▼ Q3 FY2024 | Aug 4, 2024 | -11.0% | $87.90 | $85.70 | -2.50% |
| — Q2 FY2024 | Apr 30, 2024 | — | $90.10 | $95.80 | +6.33% |
Q2 FY2026+0.00%
Report Date
May 4, 2026
EPS Beat/Miss
-19.1%
Price Before
$46.80
Price After
$46.80
Q1 FY2026+3.94%
Report Date
Mar 23, 2026
EPS Beat/Miss
+0.0%
Price Before
$48.78
Price After
$50.70
Q4 FY2025-2.48%
Report Date
Nov 4, 2025
EPS Beat/Miss
-18.7%
Price Before
$64.40
Price After
$62.80
Q2 FY2025+3.12%
Report Date
May 7, 2025
EPS Beat/Miss
-23.9%
Price Before
$83.40
Price After
$86.00
Q1 FY2025-0.84%
Report Date
Mar 17, 2025
EPS Beat/Miss
+37.1%
Price Before
$71.80
Price After
$71.20
Q4 FY2024-2.15%
Report Date
Nov 4, 2024
EPS Beat/Miss
-9.3%
Price Before
$88.40
Price After
$86.50
Q3 FY2024-2.50%
Report Date
Aug 4, 2024
EPS Beat/Miss
-11.0%
Price Before
$87.90
Price After
$85.70
Q2 FY2024+6.33%
Report Date
Apr 30, 2024
EPS Beat/Miss
—
Price Before
$90.10
Price After
$95.80
Avg Beat Reaction+1.55%
Avg Miss Reaction-0.80%
Beat Rate2 / 8 quarters
Largest Move+6.33% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: 4163.SR ends December
Al-Dawaa Medical Services Company (4163.SR) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $0.72 — missing the analyst consensus of $0.89 by -19.1%. The next 4163.SR earnings date is expected around September 2, 2026.
Each quarter, investors track 4163.SR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. 4163.SR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
4163.SR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
4163.SR earnings · 5 questionsAl-Dawaa Medical Services Company's next earnings report is expected around September 2, 2026. 4163.SR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; 4163.SR historically reports after market close (AMC).
4163.SR earnings datewhen is 4163.SR earnings4163.SR next earnings datewhen does 4163.SR report earnings4163.SR earnings calendar
▸ Source: FMP · Al-Dawaa Medical Services Company SEC filings · US GAAP · Al-Dawaa Medical Services Company SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026